Workflow guide · Competitive and thematic coverage
Maintain a therapeutic-area watchlist
Organize companies by scientific and clinical relationships.
The situation
When this workflow becomes useful
An analyst covers a disease area containing public companies, private programs, multiple modalities, and rapidly changing standards of care.
Best fit
Sell-side, buy-side, independent, and corporate analysts responsible for ongoing biotech company or therapeutic-area coverage.
The challenge
Why the obvious approach breaks down
Organize companies by scientific and clinical relationships. The challenge is to preserve the source, define what changed, and connect the update to a decision instead of collecting disconnected information.
How to think about the task
The reasoning behind the workflow
An analyst covers a disease area containing public companies, private programs, multiple modalities, and rapidly changing standards of care. For research analysts, the useful response is not simply to collect more links. The task is to decide what the new information changes, which source supports it, who needs to respond, and when the question should be reviewed again.
Organize companies by scientific and clinical relationships. The challenge is to preserve the source, define what changed, and connect the update to a decision instead of collecting disconnected information. A repeatable process keeps the work proportional to the decision and creates a record that another investor, analyst, editor, or team member can understand later.
Start with the decision this work must support
“Maintain a therapeutic-area watchlist” becomes manageable when the user names the decision before opening more sources. The decision might be whether to escalate an event, update a thesis, change a calendar, commission deeper research, publish a story, or continue monitoring. A defined decision also makes it easier to exclude information that is interesting but not currently useful.
Build a source-linked change record
The core monitoring set for this workflow includes companies and programs, targets and modalities, clinical stage and evidence, upcoming catalysts, standard-of-care changes. Each material update should retain its source and previous known state. That makes timing changes, accumulating evidence, and repeated execution patterns visible instead of leaving the user with an isolated snapshot.
Turn monitoring into an owned output
A therapeutic-area watchlist connecting programs, evidence, competitors, future events, and research ownership. The output should state what changed, what remains uncertain, who owns any follow-up, and which future event will resolve the question. The analyst can interpret company news within the evolving treatment landscape instead of maintaining isolated ticker notes.
Illustrative example
Illustrative workflow: maintain a therapeutic-area watchlist
Begin with the specific company, program, portfolio exposure, audience, or competitive set in scope. Review the highest-confidence source first, compare the disclosure with the previous record, and then use secondary context only where it helps explain the change.
Complete the workflow by producing the defined deliverable rather than ending with a collection of tabs. Assign any unresolved question to an owner and set the next review around the most relevant clinical, regulatory, financial, strategic, or editorial event.
Questions to answer before making a decision
- What has changed in companies and programs, and why does it matter?
- What has changed in targets and modalities, and why does it matter?
- What has changed in clinical stage and evidence, and why does it matter?
- What has changed in upcoming catalysts, and why does it matter?
- What has changed in standard-of-care changes, and why does it matter?
The workflow
A repeatable way to do the work
- 01
Define the specific decision or research question behind “maintain a therapeutic-area watchlist.”
- 02
Set the monitored scope around companies and programs and targets and modalities.
- 03
Collect source-linked updates for clinical stage and evidence and record what changed from the prior state.
- 04
Review upcoming catalysts together with standard-of-care changes before drawing a conclusion.
- 05
Produce the required output, assign follow-up ownership, and set the next review point.
Monitoring checklist
Signals to keep visible
Common mistakes
- Starting the monitoring process without a defined decision question
- Recording the latest state without preserving its source or previous state
- Ending with collected information but no owner, conclusion, or next review
Output and outcome
What good looks like
Deliverable
A therapeutic-area watchlist connecting programs, evidence, competitors, future events, and research ownership.
Practical outcome
The analyst can interpret company news within the evolving treatment landscape instead of maintaining isolated ticker notes.
Where BioPharmSignal fits
Reduce the collection work around the decision.
Use LiveFeed and company pages for source-linked monitoring, the PDUFA Calendar for upcoming FDA milestones, and watchlists or alerts to keep the relevant tickers and keywords visible. The workflow still requires independent research and judgment.
Frequently asked questions
Who is this workflow for?
It is designed for biotech research analysts and adjacent biotech research users who need a repeatable, source-linked way to complete this task.
What should this workflow produce?
A therapeutic-area watchlist connecting programs, evidence, competitors, future events, and research ownership.
What is the practical benefit?
The analyst can interpret company news within the evolving treatment landscape instead of maintaining isolated ticker notes.
Related workflows